肺癌是全世界癌症疾病中死亡率最高的一種，其中肺癌的死因主要是癌細胞轉移的發生。在我們先前的研究中發現Troglitazone (TGZ)，一種脂肪分化轉錄因子的核內受體(Peroxisome proliferator-activated receptor γ; PPARγ)的致效劑合併阿斯匹靈(Aspirin; ASA;非選擇性COX-1和COX-2抑制劑)處理癌細胞會有強烈的加成作用，具有使肺癌細胞的細胞週期停滯和誘導細胞凋亡而達到抗癌的效果。然而，合併ASA和TGZ對於癌細胞的轉移是否有影響還沒有深入的探討。因此，我們針對ASA合併TGZ是否能夠影響肺癌細胞爬行(migration)和侵犯(invasion)及其相關機制做了更深入的探討。在傷口癒合分析(wound healing assay)和轉移盤爬行分析(transwell migration assay)中，我們發現了ASA合併TGZ比起單獨ASA或TGZ處理A549細胞株，具有更強烈的抑制細胞爬行的效果。相似的結果在轉移盤侵犯分析(transwell invasion assay)中也發現，合併ASA和TGZ處理細胞之後具有強烈抑制細胞侵犯能力的效果。我們也發現了ASA合併TGZ抑制細胞爬行的加成效果是源於PPARγ活化和COX-1、COX-2的部分參與。我們更進一步的發現到兩種藥物合併之後，會透過抑制FAK(focal adhesion kinase)和Axl(一種酪胺酸激酶受體;Receptor tyrosine kinase)的訊息傳遞影響使細胞的爬行和侵犯能力受到抑制。因此，我們的研究結果提供了新的見解，並且說明了ASA合併TGZ組合治療腫瘤細胞轉移的相關機制，並且也可能提供一個治療肺癌新的治療方式。

Lung cancer is the leading cause of cancer-related deaths worldwide and the majority of deaths in lung cancer are caused by metastasis. Our previous studies demonstrated that Troglitzone (TGZ), a peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist, combined with Asprin (ASA), a nonselective cyclooxygenase (COX) inhibitor, had synergistic anticancer effects through cell cycle arrest and apoptosis in lung cancer cells. However, the effect of combination treatment with TGZ and ASA on cancer cell metastasis has not been investigated. Thus, we continued to investigate whether the combination treatment of TGZ and ASA affects lung cancer cells migration, and invasion and to study its underlying mechanism. In wound healing assay and transwell migration assay, cell mobility was markedly suppressed by combined ASA and TGZ compared with individual treatment in A549 cells. Similar results in transewll invasion assay were obtained, the combination treatment notably inhibited cells invasion. We also found that combination treatment of ASA and TGZ suppressed migration and invasion via inhibition of FAK and Axl signaling pathways and the synergistic effect may involve PPARγ, and partially COX-1 and COX-2 dependent. My study may provide new insights into the possible mechanisms underlying the TGZ and ASA combination treatment in cancer cells migration, and may potentially provide a therapeutic strategy for lung cancer treatment.

Abdin AA, Baalash AA, Hamooda HE (2010). Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers. J Diabetes Complications 24: 168–178.

Allred CD, Kilgore MW (2005). Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol Cell Endocrinol 235: 21-29.

Arenberg VGKRCRDA, Joel B, Thannickal VJ, Kalemkerian GP, Standiford TJ (2004). Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23: 100-108.

Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM (2006). Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 20: 2009-2016.

Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, Nemenoff RA (2005). Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 24: 1412-1422.

Brenner DE, Gescher AJ (2005). Cancer chemoprevention: lessons learned and future directions. Br J Cancer 93: 735-739.

Brown E, Hogg N (1996). Where the outside meets the inside: integrins as activators and targets of signal transduction cascades. Immunol Lett 54: 189-193.

Cance Wg, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, Simkins S et al (2000). Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res 6: 2417-2423.

Caraux A, Lu Q, Fernandez N, Riou S, Di Santo JP, Raulet DH et al (2006). Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases. Nature immunology 7: 747-754.

Choy H, Milas L (2003). Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst 95: 1440-1452.

de Groot DJ, de Vries EG, Groen HJ, de Jong S (2007). Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Critical Reviews in Oncology Hematology 61: 52-69.

di Palma A, Matarese G, Leone V, Di Matola T, Acquaviva F, Acquaviva AM, Ricchi P et al (2006). Aspirin reduces the outcome of anticancer therapy in Meth A-bearing mice through activation of AKT-glycogen synthase kinase signaling. Molecular cancer therapeutics 5: 1318-1324.

Elder DJE, Paraskeva C (1998). COX-2 inhibitors for colorectal cancer. Nat Med 4: 392-393.

Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW et al (2007). COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 97: 1523-1531.

Feinstein DI, Spagnolo A, Akar C, Weinberg G P, Murphy P, Gavrilyuk VF, Dello Russo C et al (2005). Receptor independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 70: 177-188.

Fingleton B (2006). Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 11: 479-491.

Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T et al (2010). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 107: 1124-1129.

Han S, Rivera HN, Roman J (2005). Peroxisome proliferator-activated receptor-gamma ligands inhibit alpha5 integrin gene transcription in non-small cell lung carcinoma cells. Am J Respir Cell Mol Biol 32: 350-359.

Han S, Roman J (2006). Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma dependent and PPARgamma independent signal pathways. Molecular cancer therapeutics 5: 430-437.

Han S, Ritzenthaler JD, Rivera HN, Roman J (2005). Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1. American Journal of Physiology Lung Cellular Molecular Physiology 289: 419-428.

Han S, Roman J (2004). Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun 314: 1093-1099.

Hauck CR, Hsia Da, Ilic D, Schlaepfer DD (2002). v-Src SH3-enhanced interaction with focal adhesion kinase at beta 1 integrin-containing invadopodia promotes cell invasion. Journal of Biological Chemistry, 277: 12487-12490.

Hazra S, Batra Rk, Tai HH, Sharma S, Cui X, Dubinett SM (2007). Pioglitazone and rosiglitazone decrease prostaglandin E2 in non small cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 71: 1715-1720.

He Q, Pang R, Song X, Chen J, Chen H, Chen B et al (2008). Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPAR gamma Dependent and Independent Mechanisms. PPAR research 2008: 649808.

Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998). Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334: 297-314.

Hood JD, Cheresh DA (2002). Role of integrins in cell invasion and migration. Nature reviews Cancer 2: 91-100.

Huang S, Bjornsti MA, Houghton PJ (2003). Rapamycins: mechanism of action and cellular resistance. Cancer biology and therapy 2: 222-232.

Inoue K, Kawahito Y, Tsubouchi Y, Yamada R, Kohno M, Hosokawa Y et al (2001). Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer. Anticancer Res 21: 2471-2476.

Jalving M, Koornstra JJ, De Jong S, De Vries EG, Kleibeuker JH (2005). Review article: the potential of combinational regimen with non steroidal anti inflammatory drugs in the chemoprevention of colorectal cancer. Aliment Pharmacol Ther 21: 321-339.

Kim HJ, Rho YH, Choi SJ, Lee YH, Cheon H, Um JW, Sohn J et al (2005). 15 Deoxy delta12,14 PGJ2 inhibits IL-6-induced Stat3 phosphorylation in lymphocytes. Exp Mol Med 37: 179-185.

Kim JI, Lakshmikanthan V, Frilot N, Daaka Y (2010). Prostaglandin E2 promotes lung cancer cell migration via EP4 beta Arrest in c-Src signalsome. Molecular cancer research : MCR 8: 569-577.

Kim SR, Bae MK, Kim JY, Wee HJ, Yoo MA, Bae SK (2009). Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochem Biophys Res Commun 387: 342-347.

Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, Alvarez H et al (2009). The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer biology and therapy 7: 618-626.

Kulkarni AA, Thatcher TH, Olsen KC, Maggirwar SB, Phipps RP, Sime PJ (2011). PPAR-gamma ligands repress TGF beta-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. PLos one 6.

Kurth T, Hennekens CH, Buring JE, Gaziano JM (2004). Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis. current rheumatology reports 6: 351-356.

Lantuejoul S, Soria JC, Moro-Sibilot D, Morat L, Veyrenc S, Lorimier P et al (2004). Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer 90: 1222-1229.

Leeman RJ, Lui VW, Grandis JR (2006). STAT3 as a therapeutic target in head and neck cancer. Expert Opinion on Biological Therapy 6: 231-241.

Loi CM, Young M, Randinitis E, Vassos A, Koup JR (1999). Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37: 91-104.

Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF (1996). Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 3: 927-933.

Magenta G, Borenstein X, Rolando R, Jasnis MA (2008). Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3. BMC cancer 8: 47.

Manning BD, Cantley LC (2007). AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.

McLean GW, Avizienyte E, Frame MC (2003). Focal adhesion kinase as a potential target in oncology. Expert Opinion 22: 359-357.

Meng XN, Jin Y, Yu Y, Bai J, Liu GY, Zhu J et al (2009). Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer 101: 327-334.

Meric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano J-P et al (2006). Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 59: 51-64.

Mitra SK, Hanson DA, Schlaepfer DD (2005). Focal adhesion kinase: in command and control of cell motility. Nature reviews Molecular cell biology 6: 56-68.

Nemoto T, Ohashi K, Akashi T, Johnson JD, Hirokawa K (1997). Overexpression of Protein Tyrosine Kinases in Human Esophageal Cancer. Pathobiology 65: 195-203.

Osaki M, Oshimura M, Ito H (2004). PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667-676.

Paccez JD, Vasques GJ, Correa RG, Vasconcellos JF, Duncan K, Gu X et al (2012). The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene doi: 10.1038/onc.2012.89.

Pasinetti GM (1998). Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J Neurosci Res 54: 1–6.

Pawelczyk T, Kloszewska I, Sobow T (2005). [Statins--"21st century aspirin"?]. Merkur Lekarski 19: 111-114.

Picot D, Loll PJ, Garavito RM (1994). The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367: 243-249.

Pitulis N, Papageorgiou E, Tenta R, Lembessis P, Koutsilieris M (2009). IL-6 and PPARgamma signalling in human PC-3 prostate cancer cells. Anticancer Res 29: 2331-2338.

Quesnelle KM, Boehm AL, Grandis JR (2007). STAT-mediated EGFR signaling in cancer. Journal of cellular biochemistry 102: 311-319.

Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ, Keshamouni VG et al (2010). Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Molecular cancer therapeutics 9: 3221-3232.

Ralph Meuwissen , Anton Berns (2005). Mouse models for human lung cancer. Gene and development19 : 643-664.

Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA et al (1998). Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4.

Satoh T, Toyoda M, Hoshino H, Monden T, Yamada M, Shimizu H, Miyamoto K et al (2002). Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene  21: 2171-2180.

Schaller MD (2001). Paxillin: a focal adhesion-associated adaptor protein. Oncogene Res 20: 6459-6472.

Schlaepfer DD, Mitra SK, Ilic D (2004). Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692: 77-102.

Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS et al (2005). Expression of Axl in Lung Adenocarcinoma and Correlation with Tumor Progression. Neoplasia 7: 1058-1064.

Smith Wl, Langenbach R (2001). Why there are two cyclooxygenase isozymes. The Journal of Clinical Investigation 107: 1491-1496.

Stark LA, Reid K, Sansom OJ, Din FV, Guichard S, Mayer I, Jodrell DI et al (2007). Aspirin activates the NF-kappa B signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis 28: 968-976.

Subauste MC, Pertz O, Adamson ED, Turner CE, Junger S, Hahn KM (2004). Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility. J Cell Biol 165: 371-381.

Tai KY, Shieh YS, Lee CS, Shiah SG, Wu CW (2008). Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene 27: 4044-4055.

Tang H, Chen S, Wang H, Wu H, Lu Q, Han D (2009). TAM receptors and the regulation of erythropoiesis in mice. Haematologica 94: 326-334.

Tegeder I, Pfeilschifter J, Geisslinger G (2001). Cyclooxygenase independent actions of cyclooxygenase inhibitors. FASEB J 15: 2057-2072.

Tontonoz P, Hu E, Spiegelman BM (1994). Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell Press 79: 1147-1156.

Toutant M, Costa A, Studler JM, Kadare G, Carnaud M, Girault JA (2002). Alternative Splicing Controls the Mechanisms of FAK Autophosphorylation. Mol Cell Biol 22: 7731-7743.

Tsai WC, Hsu CC, Chen CP, Chen MJ, Lin MS, Pang JH (2006). Ibuprofen inhibition of tendon cell migration and down-regulation of paxillin expression. J Orthop Res 24: 551-558.

Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K et al (2000). Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 270: 400-405.

Vane JR (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature new biology 231: 232-235.

Vane JR, Bakhle YS, Botting RM (1998). Cyclooxygenases 1 and 2. Annual review of pharmacology and toxicology 38: 97-120.

Verheugt FW (1998). Aspirin, the poor man's statin? The lancent 351: 227-228.

Watkins PB, Whitcomb RW (1998). Hepatic dysfunction associated with troglitazone. N Engl J Med 338: 916-917.

Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT et al (2004). FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nature cell biology 6: 154-161.

Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, Heasley LE et al (2002). Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase independent inhibition of lung cancer cell growth. Mol Pharmacol 62: 1207-1214.

Yan KH, Yao CJ, Chang HY, Lai GM, Cheng AL, Chuang SE (2010). The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Mol Carcinog 49: 235-246.

Yanagita M, Arai H, Nakano T, Ohashi K, Mizuno K, Fukatsu A et al (2001). Gas6 induces mesangial cell proliferation via latent transcription factor STAT3. J Biol Chem 276: 42364-42369.

Yang YC, Ho TC, Chen SL, Lai HY, Wu JY, Tsao YP (2007). Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line. BMC cancer 7: doi:10.1186/1471-2407-7-216.

Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE (2006). Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 118: 773-779.